Royalty Pharma acquires partial royalty interest on Prevymis

Royalty Pharma (RPHA) to acquire a partial royalty interest on Prevymis (letermovir) from AiCuris for $220M.

Prevymis is licensed by Merck, is approved for prophylaxis (prevention) of CMV infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant who are at high risk for CMV reactivation.

https://seekingalpha.com/news/3581613-royalty-pharma-acquires-partial-royalty-interest-on-prevymis